In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease. 2 November 2022
Pharmaceutical
Shares of Danish diabetes care giant Novo Nordisk were up 6.4% at 852.60 kroner by mid-afternoon today, after it released financial results, showing that sales increased by 26% in Danish kroner and by 16% at constant exchange rates (CER) to 128.9 billion kroner ($17.12 billion) in the first nine months of 2022. 2 November 2022
Pharmaceutical
Third quarter 2022 revenues of £7.8 billion ($9 billion) for GSK represent a significant outperform by most analysts’ lights - the consensus ahead of results day was £7.3 billion, according to data from the FT. 2 November 2022
Pharmaceutical
Rigel Pharmaceuticals’ share were up 3.4% at $0.75 yesterday, after it announced encouraging top-line efficacy and safety results from the FOCUS Phase III clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors. 2 November 2022
Biotechnology
A landmark approval in infectious diseases could be achieved by the end of the year, after New York pharma giant Pfizer reported fast progress in its respiratory syncytial virus (RSV) vaccine program. 2 November 2022
Biotechnology
Spain's AELIX Therapeutics, a spin-off of the HIVACAT vaccine research consortium, has published in Nature results from the AELIX-002 trial. 2 November 2022
Pharmaceutical
US healthcare giant Johnson & Johnson yesterday revealed it is making its largest acquisition in six years and potentially one of the biggest deals by a pharma this year. 2 November 2022
Biosimilars
Four years after it was established, Syna Therapeutics has just signed an exclusive license agreement with Indian drugmaker Intas Pharmaceuticals and its wholly-owned subsidiary Accord Healthcare for the marketing worldwide of its biosimilar medicine LB-0702 to treat pathologies in the field of hematology. 2 November 2022
Pharmaceutical
Continuing its extraordinary ascent, the world’s largest pharmaceutical firm, Pfizer, reported solid financial results in the third quarter, with revenues of $22.6 billion. 1 November 2022
Biotechnology
Switzerland-headquartered antibody-drug conjugate specialist ADC Therapeutics today announced the appointment of Kristen Harrington-Smith as chief commercial officer, effective November 17, 2022, and Peter Graham as chief legal officer, effective today. 1 November 2022
Pharmaceutical
US pharma major Eli Lilly saw its shares fall more than 4.7% to $344.91, after it released third-quarter 2022 financial results, along with a lowered full-year guidance. 1 November 2022
Pharmaceutical
The share of US pharma giant Pfizer’s erectile dysfunction drug Viagra (sildenafil) in the Russian market is steadily declining, due to the ever-growing competition from local generics and serious interruptions with supplies of the drug from Europe. 1 November 2022
Pharmaceutical
A new prefilled autoinjector pen for diabetics, Ogluo (glucagon) has been launched in Germany by Tetris Pharma, a subsidiary of British firm Arecor Therapeutics. 1 November 2022
Biotechnology
Adding to a string of recent research collaborations, Japanese drugmaker Ono Pharmaceutical has signed a drug discovery agreement for drugs in the immuno-oncology field with Swiss biotech Memo Therapeutics (MTx), an innovator in the field of antibody discovery and development. 1 November 2022
Biotechnology
US pharma major AbbVie communicated during its third-quarter financial results on October 28, that it has decided to stop the development of cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by French firm Inventiva and AbbVie for the treatment of autoimmune diseases. 1 November 2022
Pharmaceutical
Trouble recruiting patients has thrown a wrench in the works of efforts to develop a novel prostate cancer treatment, EPI-7386. 1 November 2022
Generics
The Russian capital Moscow is expected to be one of the centers for the production of new vital and essential drugs in the country already in the short term as its pharmaceutical output is steadily growing, according to recent statements by the Moscow city senior state officials and local media, reports The Pharma Letter’s local correspondent. 1 November 2022
Biotechnology
Long available in Europe under an emergency nod, AstraZeneca's COVID-19 vaccine, Vaxzevria, has finally been granted full approval in the region. 1 November 2022
Biotechnology
Having soared as much as 164% earlier in the day, shares of USA-based Coeptis Therapeutics closed down 45% at $6.50 on the Nasdaq, after it announced the completion of its business combination with Bull Horn Holdings, a special purpose acquisition company (SPAC). 1 November 2022
Pharmaceutical
Drug-resistant pathogens have increased over the past few years and no longer respond to available antibiotics. A new study in India has noted that infections that were once easily treatable are now more difficult to treat, reports The Pharma Letter’s India correspondent. 1 November 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze